Nina Capital

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.

Sonar is a healthcare company focusing on the proactive identification and intervention of mental health challenges in youth.

Connective Health specializes in developing a digital healthcare system that offers clinical-grade summaries and real-time insights for patients within electronic health records (EHR). The company's platform consolidates critical information regarding a patient's medical history, including previous care experiences, findings, medications, and diagnoses. By providing these comprehensive summaries, Connective Health enhances the ability of care providers to deliver efficient and effective treatment, while also offering insights into behavioral care. This focus on streamlining patient information aims to save time for healthcare professionals and improve overall patient outcomes.

Selfii is a healthcare data collection platform used to support monetization of patient-consented data. Its platform helps individuals and organizations harness the full potential of their health records. It collects healthcare data from diverse sources, including electronic health records (EHRs) and patient-generated data, to allow patients access a comprehensive view of their health records in one place.

Noah Labs is a technology company focused on developing software-based medical devices for the early detection of cardiovascular diseases through voice analysis. Their innovative digital health platform leverages voice-based machine learning to monitor patients and identify digital biomarkers, facilitating personalized and predictive virtual care. By utilizing this novel technology, Noah Labs aims to enhance patient outcomes, allowing individuals with cardiovascular conditions to lead healthier and longer lives from the comfort of their homes.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in developing a cloud-based platform for radiology data tailored to the needs of medical companies. Established in 2019, Segmed provides extensive clinical data and diagnostic-grade medical images to support the life sciences and technology sectors. The platform is designed to facilitate the rapid discovery and development of predictive models, thereby improving patient recruitment and data management. It offers curated and anonymized data specifically for medical artificial intelligence companies, helping to build infrastructure and data pipelines for accessing de-identified, structured, and diverse medical imaging data. Segmed's solutions aim to enhance research and regulatory processes for the pharmaceutical and medical device industries, ultimately contributing to improved global healthcare outcomes by making medical research findings more accessible, secure, and representative.

Sober Sidekick is a mobile application and telehealth platform designed to support individuals in maintaining their sobriety. The platform facilitates social engagement by connecting users with a community of peers who share similar experiences in addiction recovery. It offers tools such as a sobriety tracker and access to various addiction recovery resources, allowing users to track their progress and find encouragement in a judgment-free environment. By fostering a supportive network, Sober Sidekick aims to help individuals quit alcohol and drugs and stay committed to their recovery journey.

Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.

Quantivly, Inc. is a technology company based in Somerville, Massachusetts, that specializes in artificial intelligence solutions for radiology. Founded in 2019, it focuses on developing software that manages and analyzes MRI imaging workflows. The company's platform enables radiology providers to access a vendor-neutral, granular source of operational data by analyzing and harmonizing scanner information. This capability supports radiology departments and imaging centers in making data-driven decisions, improving operational efficiency, and enhancing patient-centered healthcare. By offering tools for data liquidity and analysis, Quantivly aims to increase access to medical imaging and drive advancements in research and patient care within the radiology sector.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.

QuantHealth develops artificial intelligence-based software aimed at enhancing drug development processes. The company's platform conducts patient-centric simulations that integrate various data points from the clinical and drug development landscape. By predicting patient responses to both existing and new therapies, QuantHealth enables pharmaceutical and biotechnology companies to test different clinical trial designs. This capability helps optimize trial strategies, ultimately increasing the chances of successful outcomes. Through its innovative approach, QuantHealth supports the healthcare industry in identifying new clinical opportunities and refining development strategies.

Lillian is building a nationwide network of health facilities in Germany.

Basys.ai is a company that specializes in automating prior authorization and utilization management for health plans and payers through an AI-driven platform. Its proprietary technology employs machine learning to digitize and encode payer policies, significantly reducing the time needed for implementation by up to nine months. The platform aims to enhance communication between patients and healthcare providers, streamline administrative processes, and improve patient outcomes. By focusing on a data-centric approach, Basys.ai helps organizations optimize care delivery while minimizing costs associated with administrative tasks and medical procedures.

Alfie Health is a virtual obesity management clinic that utilizes proprietary AI technology to support weight loss through a combination of precision medicine and behavioral change. The platform allows patients to engage in weight management from the comfort of their homes by collecting medication history and patient data, and conducting lab tests to assess metabolism. Additionally, Alfie Health connects patients with certified health coaches, providing ongoing medical supervision and support through regular telehealth visits. This comprehensive approach aims to guide users in selecting the most effective medications and strategies for sustainable weight loss.

Sober Sidekick is a mobile application and telehealth platform designed to support individuals in maintaining their sobriety. The platform facilitates social engagement by connecting users with a community of peers who share similar experiences in addiction recovery. It offers tools such as a sobriety tracker and access to various addiction recovery resources, allowing users to track their progress and find encouragement in a judgment-free environment. By fostering a supportive network, Sober Sidekick aims to help individuals quit alcohol and drugs and stay committed to their recovery journey.

Adora Health is a digital health company focused on supporting women's health during menopause. It has developed a female health application that leverages natural language processing and artificial intelligence to provide personalized advice and resources. The platform offers a range of tools, including telehealth services and lifestyle recommendations, aimed at helping women manage their health, well-being, and nutrition during this transitional phase. By integrating advanced technology with user-friendly features, Adora Health seeks to empower women to take control of their health and improve their quality of life during menopause.

Hypercare operates a healthcare coordination platform designed to enhance clinical communication and collaboration among providers. This platform addresses the growing complexity of patient care, which often requires input from multiple providers across various departments and specialties. Traditional communication methods in hospitals, such as switchboards and pagers, have proven ineffective, resulting in delays in patient care and suboptimal outcomes. Hypercare's solution facilitates secure and efficient communication among healthcare professionals in diverse settings, including hospitals, long-term care facilities, and community care organizations. By enabling providers to connect quickly and effectively, Hypercare aims to minimize interruptions and improve patient-centered care while ensuring the protection of personal health information.

CalmiGo specializes in developing a portable, drug-free device aimed at providing immediate relief from emotional and mental distress, such as anxiety and stress. Utilizing advanced patented technology, the device helps users regulate their breathing patterns and stimulates their senses to alleviate symptoms on the spot. It is designed for ease of use, making it accessible to individuals of all ages and varying technical abilities, regardless of their location. By offering a natural solution, CalmiGo addresses the need for effective stress management without reliance on pharmaceuticals.

Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.

Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.

Chiefy is a healthcare company based in New York that focuses on enhancing surgical safety and efficiency through a collaborative platform designed for perioperative teams. Founded in 2020 by Maya Ber Lerner and Assaf Ziv, Chiefy's platform facilitates asynchronous virtual huddles that allow surgeons, anesthesiologists, nurses, and other stakeholders to align on case plans prior to surgery. By capturing lessons, notes, and feedback post-procedure, Chiefy promotes continuous improvement and streamlined communication among medical teams. This approach not only automates administrative tasks but also integrates quality and best communication practices into daily operations, ultimately improving patient care and fostering smarter collaboration within surgical environments.

Hi.health is focused on transforming the claims process in private health insurance by addressing inefficiencies and enhancing cost control for insurers. The company offers a solution that includes co-branded debit cards for insurance members, allowing them to access health-related services without incurring out-of-pocket expenses. This approach not only simplifies the user experience but also provides insurers with structured data and real-time visibility into claims costs, helping to minimize fraud and operational expenses. Additionally, the platform manages invoices and prescriptions, further streamlining the insurance process and encouraging cost-conscious behavior among members. Through these innovations, Hi.health aims to deliver significant improvements in user satisfaction and substantial cost savings for insurers.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, focused on developing a machine platform for the large-scale industrial manufacturing of personalized cell therapies aimed at treating cancer. The company leverages innovative semiconductor technology and microfluidic processing to achieve real-time control and manipulation at the cellular level. This approach facilitates a fully automated and modular manufacturing system, which enhances the efficiency and safety of producing advanced cell therapies tailored to individual patient needs. Sarcura's platform represents a significant shift in manufacturing paradigms, contributing to more accessible and cost-effective treatment options for patients. The company operates from Hinterstoder, Austria.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in developing a cloud-based platform for radiology data tailored to the needs of medical companies. Established in 2019, Segmed provides extensive clinical data and diagnostic-grade medical images to support the life sciences and technology sectors. The platform is designed to facilitate the rapid discovery and development of predictive models, thereby improving patient recruitment and data management. It offers curated and anonymized data specifically for medical artificial intelligence companies, helping to build infrastructure and data pipelines for accessing de-identified, structured, and diverse medical imaging data. Segmed's solutions aim to enhance research and regulatory processes for the pharmaceutical and medical device industries, ultimately contributing to improved global healthcare outcomes by making medical research findings more accessible, secure, and representative.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

IMA Contigo, developed by BERDAC Smart Services S.L., is an innovative tablet dispenser designed to assist individuals in managing their medication schedules. Based in Barcelona, Spain, the device alerts users when it is time to take their medication, effectively reducing the risk of forgetfulness and errors in medication intake. By prioritizing user-friendliness, IMA aims to enhance patient adherence to prescribed treatments and ultimately improve health outcomes.

Leuko Labs focuses on developing a non-invasive device for monitoring white blood cell counts, which is crucial for various medical situations, including chemotherapy management and the detection of severe infections. Their device, PointCheck, allows for frequent testing without the need for blood draws or laboratory infrastructure, making it more accessible for patients. This innovation aims to enhance the quality of life for immunosuppressed individuals and improve clinical outcomes by enabling healthcare providers to offer personalized treatment plans based on real-time data. By simplifying the process of white blood cell assessment, Leuko Labs contributes to more effective patient management and better survival rates.

Healee is a health technology company that offers a telehealth platform designed to streamline online consultations between patients and healthcare providers. The platform enhances patient-doctor communication by enabling tracking and sharing of health status, as well as facilitating easy access to medical advice through virtual interactions. Healee's adaptable technology allows healthcare organizations to implement customized virtual care models, ensuring a fully-branded patient experience while integrating seamlessly with existing systems such as electronic health records, e-prescription, and billing. This comprehensive solution aims to reduce digital fatigue by consolidating various tools into one platform, ultimately improving clinical workflows and enhancing the overall healthcare experience for both providers and patients.

Formulator is a mental healthcare platform designed to enhance the efficiency and effectiveness of mental health professionals and their clients. The solution streamlines the case formulation process, enabling individuals to articulate their situations and goals clearly. This structured approach facilitates better communication between clients and clinicians, ensuring that healthcare providers can address underlying issues more effectively from the outset. By automating initial steps, Formulator improves productivity and accessibility in mental health care, ultimately leading to better outcomes for patients.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

QuantHealth develops artificial intelligence-based software aimed at enhancing drug development processes. The company's platform conducts patient-centric simulations that integrate various data points from the clinical and drug development landscape. By predicting patient responses to both existing and new therapies, QuantHealth enables pharmaceutical and biotechnology companies to test different clinical trial designs. This capability helps optimize trial strategies, ultimately increasing the chances of successful outcomes. Through its innovative approach, QuantHealth supports the healthcare industry in identifying new clinical opportunities and refining development strategies.

MySecondEar is an e-commerce company specializing in hearing aids and accessories. It provides a seamless digital experience for customers, managing the entire process from consultation to fitting and adjustments online. With a range of options available, MySecondEar aims to enhance the auditory experience for its users. The company also offers support through hearing care professionals who are accessible for inquiries via an online form on their website, ensuring customers receive the assistance they need.

Taika3D Oy specializes in 3D design automation, particularly for the orthotics and prosthetics industry. The company's platform leverages 3D scanning and intelligent machine vision to rapidly capture images and generate 3D models, facilitating the creation of custom designs with remarkable speed and consistency. This innovation addresses the challenge of producing complex custom designs efficiently, significantly reducing design time by over 95%. Additionally, Taika3D’s technology enhances production scalability, minimizes errors and returns, and supports real-time design reviews. By streamlining the design process, Taika3D empowers laboratories to harness the advantages of 3D printing for mass customization, while also preserving the expertise of their teams. The applications of their technology extend beyond orthotics and prosthetics, encompassing various sectors that require precise and modular product creation.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.

Quantivly, Inc. is a technology company based in Somerville, Massachusetts, that specializes in artificial intelligence solutions for radiology. Founded in 2019, it focuses on developing software that manages and analyzes MRI imaging workflows. The company's platform enables radiology providers to access a vendor-neutral, granular source of operational data by analyzing and harmonizing scanner information. This capability supports radiology departments and imaging centers in making data-driven decisions, improving operational efficiency, and enhancing patient-centered healthcare. By offering tools for data liquidity and analysis, Quantivly aims to increase access to medical imaging and drive advancements in research and patient care within the radiology sector.

Neuroute is an AI-driven platform that enhances the efficiency of clinical trials by optimizing patient recruitment. It offers a web-based solution that empowers healthcare professionals to connect with patients and streamline clinical development processes. By utilizing artificial intelligence, Neuroute generates targeted patient recruitment strategies and campaigns, which aim to improve outcomes for both patients and clinical innovators. The company is supported by prominent pharmaceutical firms, including Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche, and Eli Lilly, highlighting its credibility and commitment to advancing healthcare.

Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.

Hi.health is focused on transforming the claims process in private health insurance by addressing inefficiencies and enhancing cost control for insurers. The company offers a solution that includes co-branded debit cards for insurance members, allowing them to access health-related services without incurring out-of-pocket expenses. This approach not only simplifies the user experience but also provides insurers with structured data and real-time visibility into claims costs, helping to minimize fraud and operational expenses. Additionally, the platform manages invoices and prescriptions, further streamlining the insurance process and encouraging cost-conscious behavior among members. Through these innovations, Hi.health aims to deliver significant improvements in user satisfaction and substantial cost savings for insurers.

MedAll is a training platform aimed at healthcare professionals and students, functioning as a virtual medical school. It allows healthcare organizations to deliver and store their training courses, conferences, and teaching sessions in one centralized location, facilitating international sharing of educational resources. The platform enhances healthcare training by providing tools for organizing training materials, feedback, and documentation, such as certificates and schedules, in a paperless format. This comprehensive approach supports both individuals and teams in managing their professional development and improving the quality of healthcare training worldwide.

Alfie Health is a virtual obesity management clinic that utilizes proprietary AI technology to support weight loss through a combination of precision medicine and behavioral change. The platform allows patients to engage in weight management from the comfort of their homes by collecting medication history and patient data, and conducting lab tests to assess metabolism. Additionally, Alfie Health connects patients with certified health coaches, providing ongoing medical supervision and support through regular telehealth visits. This comprehensive approach aims to guide users in selecting the most effective medications and strategies for sustainable weight loss.

Cardiomatics specializes in cloud-based artificial intelligence software for the analysis of electrocardiogram (ECG) data. The company has developed a medical-grade system that employs proprietary algorithms validated against arrhythmia databases and clinical data. This technology ensures high-quality and reliable outcomes for healthcare providers. Cardiomatics collaborates with physicians, manufacturers, and ECG device providers worldwide, facilitating the delivery of clear and concise reports that enhance diagnostic accuracy and streamline clinical workflows.

Lena Health is a developer of a text-based virtual assistant platform designed to assist patients, particularly those with chronic conditions. The platform leverages conversational AI to facilitate care coordination and navigation tasks, while also providing the option for human support when needed. By allowing patients to schedule appointments and manage their health via SMS text live chat, Lena Health offers a convenient alternative to lengthy phone calls. This service is especially beneficial for value-based care organizations and payers, as it enhances medication adherence and aims to improve overall health outcomes for its members.

The Lowdown is an online platform based in London that serves as a comprehensive resource for women's contraception and reproductive healthcare. Founded in 2019, it enables women to explore and select suitable contraceptive methods through a community-driven approach. Users can share their experiences with various contraceptives, including side effects and symptoms, to provide real-world insights and advice. This user-generated content, combined with medical guidance, empowers women to make informed decisions about their healthcare. The Lowdown aims to enhance women's control over their reproductive health by facilitating access to reliable information and support.

Promptly is a health data analytics company focused on collecting, integrating, and analyzing data related to patient outcomes. The company has developed proprietary technology that facilitates patient engagement and real-world data collection, allowing for the discovery of digital biomarkers linked to symptoms, adverse effects, and treatment outcomes. By partnering with innovative healthcare organizations, Promptly utilizes this health data to enhance the quality of care while reducing costs for patients. The technology not only anticipates patient experiences before treatment but also tracks progress during treatment and provides validated information about clinical conditions, symptoms, and recovery strategies. This approach empowers patients to better understand and monitor the outcomes of their medical treatments.

EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.

MoveUP is a company focused on developing and commercializing digital therapeutics solutions designed to enhance healthcare delivery. Its innovative platform features a closed-loop system that ensures high compliance and improved outcomes for patients. By continuously collecting data, the platform personalizes treatment plans, significantly enhancing patient satisfaction. MoveUP's initial product targets orthopedic patients recovering from joint surgery, providing a user-friendly medical-grade mobile application that supports faster recovery. The company holds CE medical device and ISO 13485 certifications, underscoring its commitment to quality and regulatory standards in the healthcare sector.

contextflow GmbH is a company based in Vienna, Austria, specializing in machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, it has developed a 3D image-based search engine that enables radiologists to quickly identify regions of interest in medical images, particularly in lung CT scans. This technology allows for the rapid retrieval of similar cases and relevant clinical information, enhancing decision-making processes in diagnostics. contextflow's software is designed to integrate seamlessly with existing radiology workflows, thereby improving efficiency and patient care. The company has established strategic partnerships with various organizations, including radiology centers and health associations, and is currently conducting trials of its software with multiple partners. Recognized for its innovation, contextflow has received several awards and was selected to participate in an accelerator program aimed at advancing health technology.

Replica Analytics Ltd. is a Canadian company based in Ottawa, established in 2019, that specializes in creating modeling software for generating synthetic data from real clinical datasets. The company employs advanced machine learning techniques to produce privacy-protective synthetic data that retains the statistical properties of actual data, ensuring high utility while adhering to global privacy regulations. In addition to generating this synthetic data, Replica Analytics provides supporting documentation that outlines the utility characteristics of the data, allowing businesses to analyze and utilize data effectively without compromising privacy.

BioLib Technologies ApS operates a biomedical data analysis platform that emphasizes zero-knowledge analysis of biological and health data. Founded in 2019 and based in Copenhagen, Denmark, BioLib provides end-to-end bioinformatic data analytics services. This includes access to diverse datasets, analytic workflows, and algorithms, along with cloud-computing infrastructure and scientific support. By facilitating a secure and collaborative environment, BioLib enables companies to accelerate scientific discovery from raw experimental data to new treatments and diagnostics. The platform is designed to support both data holders and analytics specialists, enhancing the efficiency and safety of bioinformatics and diagnostic technologies.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in developing a cloud-based platform for radiology data tailored to the needs of medical companies. Established in 2019, Segmed provides extensive clinical data and diagnostic-grade medical images to support the life sciences and technology sectors. The platform is designed to facilitate the rapid discovery and development of predictive models, thereby improving patient recruitment and data management. It offers curated and anonymized data specifically for medical artificial intelligence companies, helping to build infrastructure and data pipelines for accessing de-identified, structured, and diverse medical imaging data. Segmed's solutions aim to enhance research and regulatory processes for the pharmaceutical and medical device industries, ultimately contributing to improved global healthcare outcomes by making medical research findings more accessible, secure, and representative.

PlenOptika, Inc. is a Massachusetts-based company that develops innovative optical technology to improve access to eye care. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium, PlenOptika focuses on creating solutions for the over one billion people worldwide affected by low vision. Their flagship product, QuickSee, is a handheld device that accurately measures refractive errors in the eye at the push of a button, facilitating the determination of eyeglass prescriptions. This technology is particularly beneficial in rural and low-resource settings, addressing the challenges of traditional autorefractors, which are often costly and cumbersome. PlenOptika's mission is to make eye care accessible and straightforward for everyone, especially underserved communities. The company has received recognition from various international social innovation foundations and has partnered with research institutions in the United States, Spain, and India to advance its groundbreaking technology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, focused on developing a machine platform for the large-scale industrial manufacturing of personalized cell therapies aimed at treating cancer. The company leverages innovative semiconductor technology and microfluidic processing to achieve real-time control and manipulation at the cellular level. This approach facilitates a fully automated and modular manufacturing system, which enhances the efficiency and safety of producing advanced cell therapies tailored to individual patient needs. Sarcura's platform represents a significant shift in manufacturing paradigms, contributing to more accessible and cost-effective treatment options for patients. The company operates from Hinterstoder, Austria.

EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.

contextflow GmbH is a company based in Vienna, Austria, specializing in machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, it has developed a 3D image-based search engine that enables radiologists to quickly identify regions of interest in medical images, particularly in lung CT scans. This technology allows for the rapid retrieval of similar cases and relevant clinical information, enhancing decision-making processes in diagnostics. contextflow's software is designed to integrate seamlessly with existing radiology workflows, thereby improving efficiency and patient care. The company has established strategic partnerships with various organizations, including radiology centers and health associations, and is currently conducting trials of its software with multiple partners. Recognized for its innovation, contextflow has received several awards and was selected to participate in an accelerator program aimed at advancing health technology.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in developing a cloud-based platform for radiology data tailored to the needs of medical companies. Established in 2019, Segmed provides extensive clinical data and diagnostic-grade medical images to support the life sciences and technology sectors. The platform is designed to facilitate the rapid discovery and development of predictive models, thereby improving patient recruitment and data management. It offers curated and anonymized data specifically for medical artificial intelligence companies, helping to build infrastructure and data pipelines for accessing de-identified, structured, and diverse medical imaging data. Segmed's solutions aim to enhance research and regulatory processes for the pharmaceutical and medical device industries, ultimately contributing to improved global healthcare outcomes by making medical research findings more accessible, secure, and representative.

Neurescue ApS, based in Copenhagen, Denmark, specializes in the development of medical devices aimed at treating cardiac arrest and hemorrhage. Founded in 2014, the company focuses on creating innovative cardiovascular solutions for emergency patients. Its flagship product, the safeREBOA device, is notable for being the first computer-aided aortic occlusion catheter, designed to enhance resuscitation rates and extend treatment time for critical patients. Neurescue is committed to advancing clinical practices through intelligent medical devices that aim to improve patient outcomes in emergency situations.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

PlenOptika, Inc. is a Massachusetts-based company that develops innovative optical technology to improve access to eye care. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium, PlenOptika focuses on creating solutions for the over one billion people worldwide affected by low vision. Their flagship product, QuickSee, is a handheld device that accurately measures refractive errors in the eye at the push of a button, facilitating the determination of eyeglass prescriptions. This technology is particularly beneficial in rural and low-resource settings, addressing the challenges of traditional autorefractors, which are often costly and cumbersome. PlenOptika's mission is to make eye care accessible and straightforward for everyone, especially underserved communities. The company has received recognition from various international social innovation foundations and has partnered with research institutions in the United States, Spain, and India to advance its groundbreaking technology.

TeiaCare is a health technology company focused on enhancing care in long-term care facilities through the use of artificial intelligence. Their primary solution, ANCELIA, automates the collection and analysis of resident data to improve management and care delivery. By generating smart alerts, reminders, and comprehensive reports, TeiaCare helps nursing homes optimize the monitoring of post-acute hospital patients, thereby addressing inefficiencies in care. The aim is to empower healthcare workers and managers, allowing them to extend high-quality assistance to more residents without increasing workload. TeiaCare's approach emphasizes personalized care, objective data analysis, and transparency, ultimately driving a new model of assistance that enhances the quality of life for residents while streamlining operational processes for care providers.

contextflow GmbH is a company based in Vienna, Austria, specializing in machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, it has developed a 3D image-based search engine that enables radiologists to quickly identify regions of interest in medical images, particularly in lung CT scans. This technology allows for the rapid retrieval of similar cases and relevant clinical information, enhancing decision-making processes in diagnostics. contextflow's software is designed to integrate seamlessly with existing radiology workflows, thereby improving efficiency and patient care. The company has established strategic partnerships with various organizations, including radiology centers and health associations, and is currently conducting trials of its software with multiple partners. Recognized for its innovation, contextflow has received several awards and was selected to participate in an accelerator program aimed at advancing health technology.

MindPeak GmbH, founded in 2018 and headquartered in Hamburg, Germany, specializes in developing artificial intelligence software tools aimed at enhancing cancer diagnostics. The company's flagship product, BreastAI, facilitates the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. By automating tasks such as cell and biomarker quantification, MindPeak's solutions improve the efficiency of pathologists, allowing them to focus on critical decision-making in cancer treatment. The company also maintains a strategic relationship with Gestalt Diagnostics, further expanding its impact in the field of diagnostic automation. Through its innovative platform, MindPeak strives to make microscopical analysis more accessible and cost-effective in clinical environments.

Kheiron Medical Technologies Limited is a company focused on enhancing breast cancer detection through its innovative product, Mia, an intelligent assessment tool for mammography. Incorporated in 2016 and based in London with additional offices in San Francisco, Budapest, and Amsterdam, Kheiron aims to improve the efficiency, consistency, and accuracy of radiology reporting by integrating advanced deep learning techniques with radiological expertise. The company's mission is to radically enhance outcomes for cancer patients by advancing precision radiology, thereby providing women with better chances in the fight against cancer. Through ongoing research and development, Kheiron strives to transform cancer detection and treatment, marking a significant step forward in the realm of healthcare technology.

Leuko Labs focuses on developing a non-invasive device for monitoring white blood cell counts, which is crucial for various medical situations, including chemotherapy management and the detection of severe infections. Their device, PointCheck, allows for frequent testing without the need for blood draws or laboratory infrastructure, making it more accessible for patients. This innovation aims to enhance the quality of life for immunosuppressed individuals and improve clinical outcomes by enabling healthcare providers to offer personalized treatment plans based on real-time data. By simplifying the process of white blood cell assessment, Leuko Labs contributes to more effective patient management and better survival rates.